Oslo, 14 November 2022. Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX),
a Norwegian immuno-oncology company, today announces site activation for the
ATLAS-IT-05 study in three European countries.

ATLAS-IT-05 is a Phase II combination study evaluating LTX-315 and pembrolizumab
in patients with advanced melanoma. The study was initiated at MD Anderson
Cancer Center in 2021 and is currently ongoing in the US. The objective of the
study is to document whether LTX-315 in combination with pembrolizumab is
effective in inducing tumor responses in patients who have failed prior anti PD
1/PD L1 immune checkpoint therapy. 

The clinical trial has now been extended to Spain, France and Norway and sites
are opened in all three countries. The expansion of the site network will
mitigate recruitment challenges, drive enrollment towards completion and extend
the clinical impact field for LTX-315. The European branch of the study is
performed at highly recognized sites with intratumoral immunotherapy expertise,
led by melanoma experts at each site. It will follow the same protocol as in the
US. 

The regulatory application in Europe was approved in Q3 2022, and efforts to
initiate recruitment of patients is ongoing with the aim to complete enrollment
in the study in early 2023.


"We are very pleased to now be able to recruit patients in three European
countries that will help us to complete the ongoing ATLAS-IT-05 Phase II study",
says CEO and Co-founder of Lytix Biopharma, Øystein Rekdal. 


For more information, please contact: 
Ole Peter Nordby, ole.peter.nordby@lytixbiopharma.com

Lytix Biopharma in brief: 
Based in Oslo, Norway, Lytix is a clinical stage biotech company developing
novel cancer immunotherapies, an area within cancer therapy that is aimed at
activating the patient's immune system to fight cancer. The company's technology
is based on pioneering research in "host defense peptides" - nature's first line
of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315,
is a first-in-class oncolytic molecule representing a new and superior
therapeutic principle to boost anti-cancer immunity, with the potential to be
the ideal combination partner with other types of immunotherapies. LTX-315
targets cancer cells and disintegrates their cell membranes, causing immunogenic
cell death and release of a patient's tumor specific antigens and potent
immunostimulants. This mode of action allows cytotoxic T cells to recognize,
infiltrate and attack cancer cells.